The C.A.M. Report
Complementary and Alternative Medicine: Fair, Balanced, and to the Point
  • About this web log

    This blog ran from 2006 to 2016 and was intended as an objective and dispassionate source of information on the latest CAM research. Since my background is in pharmacy and allopathic medicine, I view all CAM as advancing through the development pipeline to eventually become integrated into mainstream medical practice. Some will succeed while others fail. But all are treated fairly here.

  • About the author

    John Russo, Jr., PharmD, is president of The MedCom Resource, Inc. Previously, he was senior vice president of medical communications at, a complementary and alternative medicine website.

  • Common sense considerations

    The material on this weblog is for informational purposes. It is not medical advice or counsel. Be smart, consult your health professional before using CAM.

  • Recent Posts

  • Recent Comments

    Omega-3 and the nephrotic syndrome

    Nephrotic-range proteinuria is defined as urinating more than 3.5 grams of protein per day. That’s 25 times the normal amount, and is the primary indicator of the nephrotic syndrome — a group of diseases that damage the kidneys’ filtering system.

    Researchers at the Glasgow Royal Infirmary in the United Kingdom looked at the effect of omega-3 fatty acids.

    First, the details.

    • 17 patients with nephrotic range proteinuria were compared to 17 age and sex matched controls.
    • Lipid blood levels after eating were assessed before and after 8 weeks of treatment with 4 gram daily of omega-3 fatty acids (Omacor, Lovaza).
    • A standard fat load (90 grams) was administered and blood samples of lipids were taken before and 2, 4, 6, and 8 hours later.

    And, the results.

    • Before treatment, chylomicron triglycerides (small fat globule composed of protein and fat) in the patients with nephrotic syndrome were significantly greater vs the control group.
    • Following omega-3 treatment chylomicrons fell significantly in the patients with nephrotic syndrome.
    • There was no reduction in the control group.
    • Following 8 weeks of treatment with omega-3 there were no differences between the groups.

    The bottom line?
    The authors concluded that omega-3 fatty acid “would be an ideal therapy in combination with statins for this high risk group of patients.”

    1/20/09 20:49 JR

    Leave a Comment

    You must be logged in to post a comment.